Why Atossa Genetics (ATOS) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) -- Shares of Atossa Genetics  (ATOS) plummeted to a 52-week low of $1.07 on Wednesday after the company announced the FDA had determined Atossa's ForeCYTE Breast Aspirator is "not substantially equivalent" to its predicate device and would not clear it for U.S. marketing.

Atossa will now prioritize the U.S. commercialization of another breast aspirator, the FullCYTE. Atossa acquired the FullCYTE, which the FDA has already cleared, in 2012. The FullCYTE is a subset of Atossa's FullCYTE Microcather, which Atossa has been preparing to commercialize during the last 12 months.

The stock closed down 42.49% to $1.34. More than 2.6 million shares changed hands, compared to the average volume of 473,281.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ATOS Chart ATOS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday